Could an immunotherapy combo replace harsh chemo for head and neck cancer?
NCT ID NCT03529422
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether combining the immunotherapy drug durvalumab (Imfinzi) with radiation therapy can effectively treat intermediate-risk head and neck cancer after surgery, while causing fewer serious side effects than the standard cisplatin-based chemo-radiation. The study enrolls adults with certain head and neck cancers and gives them durvalumab every three weeks for six cycles along with six weeks of daily radiation. Researchers track how many patients remain cancer-free at three years and monitor for severe side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (Imfinzi) and intensity-modulated radiotherapy (IMRT)
What this could lead to
If successful, this combination could offer a less toxic alternative to standard chemotherapy plus radiation for head and neck cancer patients, potentially improving quality of life while maintaining cure rates.
What could go wrong
This is a small, early-phase study (18 participants) with no control group, so results may not apply broadly. Durvalumab is not yet approved for head and neck cancer and can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical University of South Carolina - Hollings Cancer Center
Charleston, South Carolina, 29425, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
University Of Alabama At Birmingham
Birmingham, Alabama, 35294, United States